This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
Good news for those of you with nonsense mutations or Stop mutations or X ending mutations.(Different names same mutations)
Here is the link from the phase 2 results of PTC124 in patients with CF.
Good news for those of you with nonsense mutations or Stop mutations or X ending mutations.(Different names same mutations)
Here is the link from the phase 2 results of PTC124 in patients with CF.
Good news for those of you with nonsense mutations or Stop mutations or X ending mutations.(Different names same mutations)
Here is the link from the phase 2 results of PTC124 in patients with CF.
Good news for those of you with nonsense mutations or Stop mutations or X ending mutations.(Different names same mutations)
Here is the link from the phase 2 results of PTC124 in patients with CF.
Good news for those of you with nonsense mutations or Stop mutations or X ending mutations.(Different names same mutations)
Here is the link from the phase 2 results of PTC124 in patients with CF.
Thanks for that link and updating us on the PTC124 drug that many are following with so much hope.
The presentation at annual NA CF conference where this was discussed including updates on other trials can be downloaded here:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nacfconference.org/plenary2007.htm
">http://www.nacfconference.org/plenary2007.htm
</a>
Thanks for that link and updating us on the PTC124 drug that many are following with so much hope.
The presentation at annual NA CF conference where this was discussed including updates on other trials can be downloaded here:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nacfconference.org/plenary2007.htm
">http://www.nacfconference.org/plenary2007.htm
</a>
Thanks for that link and updating us on the PTC124 drug that many are following with so much hope.
The presentation at annual NA CF conference where this was discussed including updates on other trials can be downloaded here:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nacfconference.org/plenary2007.htm
">http://www.nacfconference.org/plenary2007.htm
</a>
Thanks for that link and updating us on the PTC124 drug that many are following with so much hope.
The presentation at annual NA CF conference where this was discussed including updates on other trials can be downloaded here:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nacfconference.org/plenary2007.htm
">http://www.nacfconference.org/plenary2007.htm
</a>
Thanks for that link and updating us on the PTC124 drug that many are following with so much hope.
The presentation at annual NA CF conference where this was discussed including updates on other trials can be downloaded here:
<a target=_blank class=ftalternatingbarlinklarge href="http://www.nacfconference.org/plenary2007.htm
">http://www.nacfconference.org/plenary2007.htm
</a>
Hi I just found out my sons other mutation is R1158X. So he could benefit from PTC124 if approved? Does anyone else have R1158X? His other mutation is the F508. Thanks!
Hi I just found out my sons other mutation is R1158X. So he could benefit from PTC124 if approved? Does anyone else have R1158X? His other mutation is the F508. Thanks!
Hi I just found out my sons other mutation is R1158X. So he could benefit from PTC124 if approved? Does anyone else have R1158X? His other mutation is the F508. Thanks!
Hi I just found out my sons other mutation is R1158X. So he could benefit from PTC124 if approved? Does anyone else have R1158X? His other mutation is the F508. Thanks!
Hi I just found out my sons other mutation is R1158X. So he could benefit from PTC124 if approved? Does anyone else have R1158X? His other mutation is the F508. Thanks!
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.